JPMS, CIA and JPMCB are affiliated companies under the common control of JPMorgan Chase & Co. Certain custody and other services are provided by JPMorgan Chase Bank, N.A. (CIA), a licensed insurance agency, doing business as Chase Insurance Agency Services, Inc. Annuities are made available through Chase Insurance Agency, Inc. Morgan Securities LLC (JPMS), a registered broker-dealer and investment advisor, member FINRA and SIPC. Morgan Wealth Management is a business of JPMorgan Chase & Co., which offers investment products and services through J.P. Investing involves market risk, including possible loss of principal, and there is no guarantee that investment objectives will be achieved. is a wholly-owned subsidiary of JPMorgan Chase & Co. OptraSCAN’s end-to-end digital pathology solution provides effective acquisition of whole slide images, viewing, storing, real-time sharing, reporting and AI & ML based Image analysis solutions via On-Demand or outright purchase model.“Chase,” “JPMorgan,” “JPMorgan Chase,” the JPMorgan Chase logo and the Octagon Symbol are trademarks of JPMorgan Chase Bank, N.A. An ISO 13485 certified company and CE marked whole slide scanners for IVD use, OptraSCAN is working to eliminate the barriers to “Go Digital” no matter the size of the pathology lab, the lab’s throughput or global location. OptraSCAN® are pioneers in the On-Demand Digital Pathology® System, focused on delivering fully integrated, affordable solutions that will maximize your return on investment and improve the performance of your pathology services. The same Paige technology empowers pharmaceutical companies to more effectively evaluate treatment options for patients and design new biomarkers for drug development so that every patient gets precise treatment options.įor additional information, please visit:, Twitter and LinkedIn. Paige is the first company to receive FDA approval for a clinical AI application in digital pathology. To improve the lives of patients with cancer, Paige has created a cloud-based platform that transforms pathologists’ workflow and increases diagnostic confidence as well as productivity, all on a global scale. Paige is using the power of AI to drive a new era of cancer discovery and treatment. This partnership with Paige will facilitate adoption of digital infrastructure for global clinical and molecular pathology community in an efficient way.” “This collaboration is an important step in our mission to unlock the full potential of AI in routine clinical use and provide healthcare professionals with precise insights to help patients get the most effective care.”Ībhi Gholap, Founder and CEO of OptraSCAN said, “OptraSCAN’s mission to enable pathology slide digitization at fractional costs is eventually resulting into higher market demand for digital pathology applications. “We are excited to work with OptraSCAN to make it easier for labs and healthcare networks around the world to adopt digital pathology workflows,” said Andy Moye, Ph.D., Chief Executive Officer at Paige. OptraSCAN devices have 15 to 480 slide loading capabilities that digitize the glass slides at 40x in less than one minute per slide with patented composite imaging offering. This provides a streamlined path for pathologists to adopt Paige’s leading suite of digital pathology applications, including the FDA-cleared FullFocus® whole-slide image viewer and AI applications including Paige Prostate Suite and Paige Breast Suite alongside OptraSCAN’s affordable digital pathology scanners. Together, the companies will integrate Paige’s clinical AI applications and interoperable enterprise imaging platform with OptraSCAN’s digital pathology scanner to offer advanced end-to-end digital pathology workflow solutions. The companies aim to reduce barriers to digitizing glass pathology slides, which will in turn enhance workflows in pathology and oncology. NEW YORK-( BUSINESS WIRE)- Paige, a global leader in end-to-end digital pathology solutions and clinical AI applications, and OptraSCAN®, a leading producer of whole slide scanners, today announced a partnership to streamline the adoption of digital pathology technology in the United States, European Union countries and United Kingdom.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |